The Latest Cardiac and Vascular News
NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, today announced the publication of a new meta-analysis in the European Heart Journal’s publication Cardiovascular Pharmacotherapy, discussing the effect of cholesteryl ester transfer protein (CETP) inhibitors on new-onset diabetes. […]
Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May CAESAREA, Israel, May 10, 2022 /PRNewswire/ — Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS First-In-Human (FIH) study. Study results […]
Initial agreement includes comparison study of patient cardiac CT scans read by experts to those read by AI-based technology HUNTSVILLE, Ala., May 10, 2022 /PRNewswire/ — Artrya Ltd, creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader […]
Iocyte AMI-3 Trial to Assess Effectiveness and Safety of FDY-5301 in Improving Outcomes for Anterior STEMI Patients Undergoing Primary PCI SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy […]
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable Securities […]
Medication Copayment and Insurance Premium Assistance Now Available for Medicare Patients GERMANTOWN, Md., May 9, 2022 /PRNewswire/ — The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is pleased to announce that it has opened a new fund to assist individuals living with cardiomyopathy. Through the new […]
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in China SHANGHAI, China and PRINCETON, N.J., May 09, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN) […]
CHICAGO, May 6, 2022 /PRNewswire/ — The International Society for Heart and Lung Transplantation (ISHLT) awarded grants to three researchers its 2022 Annual Meeting. ISHLT grants fund research to improve the care of patients with advanced heart and lung disease through transplantation, mechanical circulatory support (MCS), and innovative therapies. “I am absolutely […]
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or […]
EMERYVILLE, Calif., May 4, 2022 /PRNewswire/ — Discovering new ways to treat heart and lung diseases by tapping into the natural disease resistance of hibernating animals is the focus of a new partnership between Monash University and Fauna Bio, a U.S. biotechnology company. Hibernation requires mechanisms of self-healing and tissue repair to endure […]
